Techno Venture Management

Helomics Corporation, established in 1995 and headquartered in Pittsburgh, Pennsylvania, is a personalized healthcare company specializing in cancer care. It develops and delivers a portfolio of products to aid physicians and patients in making informed clinical decisions. Helomics' core technology, the Precision Cellular Analytical Platform, collects and analyzes cell cycle and proliferation data over an extended period. Key products include ChemoFx, BioSpeciFx, GeneFx Colon, and GeneFx Lung, which help physicians select effective treatments and understand potential drug responses or prognosis. The company also offers tumor profiling services, contract research and development, and biorepository and banking services. Helomics operates as a contract research organization (CRO), providing oncology insights for six primary cancers and using artificial intelligence and its D-CHIP platform to create personalized oncology roadmaps. It serves the pharmaceutical, diagnostic, biotechnology, and research industries, aiming to improve patient outcomes through personalized treatments and diagnostics.

Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients.

Streaming21 is a solution provider of seamless on-demand and IP broadcasting service platform for connected digital home.

ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.

VPIsystems, formerly known as VPI Virtual Photonics, develops and markets network planning software and services for the telecommunications industry, both in the United States and internationally. The company offers products such as Photonic Design Automation, which models and optimizes photonic components, and OnePlan, an integrated system that assists communications service providers, systems integrators, and manufacturers in transitioning to IP-based networks. VPIsystems aims to enhance the efficiency of network planning and engineering processes through predictive network analytics, enabling clients to optimize network integration and improve overall network reliability. The company serves a diverse clientele, including wireline and wireless carriers, broadband providers, and equipment manufacturers. Founded in 1997, VPIsystems is headquartered in Holmdel, New Jersey, with additional offices in Europe, Asia, and Australia, and maintains strategic alliances with notable firms such as Accenture and HP.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

iTAC Software AG is a specialized provider of manufacturing execution systems (MES) that serves the global manufacturing industry. Founded in 1998 and headquartered in Montabaur, Germany, with an additional location in Detroit, Michigan, the company offers a range of advanced solutions designed to enhance production efficiency and facilitate Industry 4.0 applications. Its key products include iTAC.ARTES, a middleware layer for enterprise applications; iTAC.MES.Suite, which improves production processes; and iTAC.Trace.Server, aimed at companies seeking to implement autonomous production capabilities. Additionally, iTAC provides various support and consulting services, including educational programs, project preparation, and 24/7 technical assistance. The company's clientele spans multiple sectors, including automotive, electronics, medical technology, and energy. iTAC Software AG operates as a subsidiary of Dürr Aktiengesellschaft.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.

Infitel International is a provider of solutions for telecommunications value-added services based on intelligent networks (IN platforms).

Pharmasset Inc is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing innovative drugs for viral infections. The company specializes in oral therapeutics targeting hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV). Its research centers on nucleoside analogs, which inhibit enzymes essential for viral replication. Pharmasset is advancing three product candidates: Clevudine, aimed at HBV, which is expected to enter Phase 3 clinical trials; R7128, a pro-drug for HCV currently in Phase 1 trials; and Racivir, an investigational treatment for HIV in Phase 2 trials. Through these efforts, Pharmasset seeks to provide effective treatment options for patients suffering from these viral infections.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, that specializes in the discovery, development, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. The company primarily focuses on allosteric modulators, a novel class of orally available drugs that interact with G-protein coupled receptors, potentially offering advantages over traditional therapeutic approaches. Its lead product candidates include Dipraglurant for treating Parkinson's disease-related dyskinesia and dystonia, ADX71149 for epilepsy and other CNS disorders, and GABAB PAM for addiction. Addex has established a collaboration with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds aimed at addressing various health issues. Founded in 2002, Addex Therapeutics continues to advance its innovative drug discovery platform to improve therapeutic outcomes for patients with neurological conditions.

Cambridge Broadband Networks Limited specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers both in the United Kingdom and internationally. The company's flagship product, VectaStar, is a multipoint microwave platform that facilitates mobile backhaul, enterprise access, and small cell network solutions. This includes offerings such as VectaStar Gigabit for macro backhaul and enterprise access, and VectaStar Metro for multipoint microwave backhaul. Additionally, the company provides a comprehensive network management system and various support services, including consultancy, training, and project management, to assist operators in designing and deploying microwave backhaul networks. Founded in 1999 and headquartered in Cambridge, the company addresses the growing demand for enhanced network capacity and efficiency in the face of increasing mobile data usage.

Evotec Neurosciences GmbH is a biotechnology company focused on the discovery and development of small molecule drugs aimed at treating Alzheimer's disease and other neurological disorders. Through its research initiatives, the company seeks to create innovative therapeutics that address significant unmet medical needs in the field of neuroscience.

MediGene AG is a biotechnology company focused on immuno-oncology, specializing in the development of differentiated T Cell Receptor engineered T cell (TCR-T) therapies for treating various solid tumor indications with high unmet medical needs. Its primary operating segments are Immunotherapies and Other products, with Immunotherapies comprising T-cell receptor-based adoptive T-cell therapy and DC vaccines. MediGene operates globally, with significant revenue generated from its operations in Germany.

SelectX Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts, specializing in the discovery and development of aminoglycoside therapeutics to address unmet medical needs. The company is advancing its lead candidate, SXP2523, a next-generation aminoglycoside antibiotic aimed at treating drug-resistant gram-negative infections acquired in hospital settings. Additionally, SelectX is developing an inhaled aminoglycoside antibiotic intended for patients with Cystic Fibrosis and other respiratory diseases who face similar drug resistance challenges. Beyond antibiotics, the company is also focused on identifying and optimizing non-antibiotic aminoglycoside leads to target critical biological pathways, including cell migration and the correction of nonsense mutations. SelectX Pharmaceuticals was originally known as OmniScience Pharmaceuticals Inc. before rebranding in September 2002.

Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.

CoreOptics specializes in providing advanced solutions for high-speed optical networking applications within the telecommunications and information technology sectors. The company is recognized for its 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, which are essential for Metro, Regional, and Long Haul optical and data networks. CoreOptics advocates for open optical communication systems that can efficiently transmit data across various rates and fiber types. Its innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is notable for enabling Tier 1 systems vendors and carriers to enhance network performance without overhauling existing fiber infrastructure. By eliminating the need for Optical Compensators and Second Stage Amplifiers, CoreOptics' products can significantly lower first-in deployment costs for customers, achieving reductions of up to 30%.

Helomics Corporation, established in 1995 and headquartered in Pittsburgh, Pennsylvania, is a personalized healthcare company specializing in cancer care. It develops and delivers a portfolio of products to aid physicians and patients in making informed clinical decisions. Helomics' core technology, the Precision Cellular Analytical Platform, collects and analyzes cell cycle and proliferation data over an extended period. Key products include ChemoFx, BioSpeciFx, GeneFx Colon, and GeneFx Lung, which help physicians select effective treatments and understand potential drug responses or prognosis. The company also offers tumor profiling services, contract research and development, and biorepository and banking services. Helomics operates as a contract research organization (CRO), providing oncology insights for six primary cancers and using artificial intelligence and its D-CHIP platform to create personalized oncology roadmaps. It serves the pharmaceutical, diagnostic, biotechnology, and research industries, aiming to improve patient outcomes through personalized treatments and diagnostics.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases. It discovers and develops antigens and adjuvants, which are derived from its proprietary technology platforms. The company was founded in 1998 and is headquartered in Vienna, Austria.

Nanostream Inc. provides products and services for pharmaceutical and biotech companies.

Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Founded in 1995 and headquartered in Ardsley, New York, the company markets Ampyra (dalfampridine), an oral drug approved by the FDA to improve walking in patients with multiple sclerosis (MS). In Europe, this drug is marketed as Fampyra. Acorda also markets Selincro for alcohol dependence in Europe and Zanaflex Capsules for spasticity management. Additionally, the company develops Inbrija for treating OFF periods in Parkinson’s disease and ARCUS for acute migraine. Other pipeline products include rHIgM22 for MS and Cimaglermin alfa for heart failure. Acorda has collaborations with Biogen Inc. for Ampyra's development and commercialization.

Sirna Therapeutics is a biotechnology company focused on developing therapies based on RNA interference (RNAi), a groundbreaking scientific discovery with the potential to transform disease treatment. By harnessing the capabilities of RNAi, Sirna Therapeutics aims to create innovative solutions that address various illnesses, positioning itself at the forefront of this emerging field. The company's commitment to advancing RNAi-based therapies highlights its role in the evolving landscape of medical treatment, with the goal of improving patient outcomes through targeted interventions.

ClearCube Technology specializes in centralized and virtualized computing solutions, having pioneered the industry with the invention of the blade PC. The company provides a comprehensive range of specialized PCoIP desktop zero clients, which connect to optimized compute and storage host platforms tailored for different user needs, including both task-oriented and highly specialized engineering applications. ClearCube's product offerings include secure zero clients with integrated security features, designed for seamless compatibility with VMware Horizon virtualization products. Their solutions are widely adopted across various sectors, including federal agencies, healthcare, and finance, where they are valued for their ability to enhance security and reduce costs in centralization and virtualization efforts. ClearCube's commitment to meeting diverse IT requirements is further exemplified through their provision of ready-to-ship VDI endpoints and customizable hardware, ensuring optimal performance and expert support for businesses across multiple industries.

Idenix Pharmaceuticals is a biopharmaceutical company focused on discovering and developing drugs for the treatment of viral diseases, primarily targeting hepatitis C virus (HCV). With operations in the United States and Europe, the company's research efforts have led to significant advancements in HCV treatment, including the completion of a proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. Idenix has also initiated a phase IIa clinical trial to evaluate its lead drug candidate, IDX184, in combination with existing therapies. In addition to HCV, Idenix is developing products and candidates aimed at treating hepatitis B virus (HBV), human immunodeficiency virus type I (HIV), and acquired immune deficiency syndrome (AIDS).

Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.

Cardion is a biopharmaceutical company that integrates synergistic local gene delivery, stem cell engineering, and tolerance induction capabilities to build cardiovascular gene therapy products. Cardion was founded in 1996 and is based in Erkrath, Nordrhein-Westfalen.

CoreOptics specializes in providing advanced solutions for high-speed optical networking applications within the telecommunications and information technology sectors. The company is recognized for its 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, which are essential for Metro, Regional, and Long Haul optical and data networks. CoreOptics advocates for open optical communication systems that can efficiently transmit data across various rates and fiber types. Its innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is notable for enabling Tier 1 systems vendors and carriers to enhance network performance without overhauling existing fiber infrastructure. By eliminating the need for Optical Compensators and Second Stage Amplifiers, CoreOptics' products can significantly lower first-in deployment costs for customers, achieving reductions of up to 30%.

Neuro3d is a biopharmaceutical start-up that aims at virtual treatment and drug development for mental and behavioral disorders.

Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, that specializes in the discovery, development, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. The company primarily focuses on allosteric modulators, a novel class of orally available drugs that interact with G-protein coupled receptors, potentially offering advantages over traditional therapeutic approaches. Its lead product candidates include Dipraglurant for treating Parkinson's disease-related dyskinesia and dystonia, ADX71149 for epilepsy and other CNS disorders, and GABAB PAM for addiction. Addex has established a collaboration with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds aimed at addressing various health issues. Founded in 2002, Addex Therapeutics continues to advance its innovative drug discovery platform to improve therapeutic outcomes for patients with neurological conditions.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Alfabet is a company that specializes in change management software aimed at enhancing enterprise information technology architecture planning. Founded in 1997 and based in Berlin, with a U.S. headquarters in Cambridge, Massachusetts, Alfabet offers its planningIT software, which integrates business priorities with IT deliverables, facilitating strategic planning and management of IT resources to align with business goals. Unlike traditional solutions that provide only static views of priorities and infrastructure, Alfabet's approach delivers a holistic, collaborative framework that ensures continuous transparency in managing evolving IT and business processes. The company serves a global community of 40,000 IT professionals across various industries, including automotive, financial services, telecommunications, and logistics. Its notable clients include major international corporations such as Credit Suisse, Munich Re, BMW, and Deutsche Bahn.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

ParadigmGenetics is a biotechnology company at the forefront of life science and gene discovery, focused on metabolic disorders. Leveraging cutting-edge technology and research methodologies, ParadigmGenetics strives to develop innovative solutions that contribute to the diagnosis, treatment, and prevention of metabolic disorders, aiming to make significant strides in the fields of biotechnology and human health.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

SelectX Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts, specializing in the discovery and development of aminoglycoside therapeutics to address unmet medical needs. The company is advancing its lead candidate, SXP2523, a next-generation aminoglycoside antibiotic aimed at treating drug-resistant gram-negative infections acquired in hospital settings. Additionally, SelectX is developing an inhaled aminoglycoside antibiotic intended for patients with Cystic Fibrosis and other respiratory diseases who face similar drug resistance challenges. Beyond antibiotics, the company is also focused on identifying and optimizing non-antibiotic aminoglycoside leads to target critical biological pathways, including cell migration and the correction of nonsense mutations. SelectX Pharmaceuticals was originally known as OmniScience Pharmaceuticals Inc. before rebranding in September 2002.

Altor BioScience Corporation, founded in 2002 and based in Miramar, Florida, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of immunotherapeutic agents aimed at treating cancer, viral infections, and autoimmune diseases. The company’s product portfolio includes several innovative candidates such as ALT-801, a T-cell receptor-targeted treatment for cancer, and ALT-803, an IL-15 superagonist for solid tumors and metastatic melanoma. Altor also develops novel monoclonal antibodies and fusion proteins, targeting conditions such as acute respiratory distress syndrome and non-small cell lung cancer. Additionally, the company offers STAR Fusion and STAR Multimer Reagents, which are utilized for the diagnosis and targeting of cancer and viral infections, as well as for research in vaccine development. Altor BioScience's focus on the immunostimulatory properties of cytokines like IL-15 and IL-2 underlines its commitment to enhancing the immune response against diseases.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

IC Mechanics specializes in the design and manufacturing of micro-electromechanical systems (MEMS) sensor integrated circuits. The company focuses on creating smart sensors that are cost-effective, highly sensitive, and capable of operating at higher bandwidths while being smaller and lighter than existing solutions. This innovation is achieved through a unique sensor geometry and a manufacturing process that utilizes commodity CMOS VLSI wafers. By exceeding current standards in cost, sensitivity, bandwidth, and mass, IC Mechanics aims to foster the development of new devices and applications across various markets. Their products are particularly targeted at original equipment manufacturers (OEMs) seeking affordable and highly integrated motion sensing and motion control solutions.

Cambridge Broadband Networks Limited specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers both in the United Kingdom and internationally. The company's flagship product, VectaStar, is a multipoint microwave platform that facilitates mobile backhaul, enterprise access, and small cell network solutions. This includes offerings such as VectaStar Gigabit for macro backhaul and enterprise access, and VectaStar Metro for multipoint microwave backhaul. Additionally, the company provides a comprehensive network management system and various support services, including consultancy, training, and project management, to assist operators in designing and deploying microwave backhaul networks. Founded in 1999 and headquartered in Cambridge, the company addresses the growing demand for enhanced network capacity and efficiency in the face of increasing mobile data usage.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

Nanostream Inc. provides products and services for pharmaceutical and biotech companies.

B-there.com provides online event management solutions for the meeting, trade show, and convention industries. It is based in Westport, Connecticut.

Curacyte GmbH is a biopharmaceutical company based in Munich, Germany, founded in 2001. It specializes in developing innovative therapeutics for acute and critical care, focusing on areas such as hematology, antithrombosis, and oncology. The company's research efforts aim to create advanced biopharmaceutics that address urgent medical needs, providing new treatment options for patients with critical diseases.

Pharmasset Inc is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing innovative drugs for viral infections. The company specializes in oral therapeutics targeting hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV). Its research centers on nucleoside analogs, which inhibit enzymes essential for viral replication. Pharmasset is advancing three product candidates: Clevudine, aimed at HBV, which is expected to enter Phase 3 clinical trials; R7128, a pro-drug for HCV currently in Phase 1 trials; and Racivir, an investigational treatment for HIV in Phase 2 trials. Through these efforts, Pharmasset seeks to provide effective treatment options for patients suffering from these viral infections.

Iolon, Inc. is a privately held company specializing in optical networking components. It develops high-performance tunable devices designed for advanced fiber optic networks. The company's initial offering is a high-powered, external cavity tunable laser source suitable for high bit rate and long-haul applications. Iolon plans to expand its product range to include tunable filters, optical switches, polarization controllers, spectral monitors, and universal transponders. The technology platform employed by Iolon supports advanced automation for high-volume manufacturing and is based on patented micro-optics, MEMS, and sophisticated servo control technologies. Their products are utilized by customers in various applications, including the transmission, monitoring, and reception of optical signals, as well as in testing and measurement equipment.

Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers proteinarray services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development. In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions. Zeptosens was founded in 2002 and is headquartered in Wilderswil, Switzerland.

Talia is a top-tier provider of Internet, voice, and video services, recognised as a market leader throughout the Middle East, Africa, and Europe. Experts in satellite, voice, video, and broadcast communications, Talia provide global network coverage, enabling enterprises, PTTs, mobile carriers, and broadcasters to connect to the largest global meet me room, and linking the major regional telecoms hubs around the world.

EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in the development of innovative pharmaceutical products aimed at treating pain and cancer. The company focuses on creating safe and effective prescription pain management solutions that utilize a topical delivery system, distinguishing itself from traditional systemic or transdermal methods. EpiCept is committed to exploring partnerships for co-marketing, co-promotion, licensing, and distribution with third-party collaborators to expand its reach in the market. The company's products are supported by a robust patent portfolio, reflecting its dedication to protecting its innovations and capitalizing on the significant market potential of its offerings.

Talia specializes in research, development, design, and production of eyecare diagnostic medical devices for the ophthalmology industry.

Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients.

CoreOptics specializes in providing advanced solutions for high-speed optical networking applications within the telecommunications and information technology sectors. The company is recognized for its 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, which are essential for Metro, Regional, and Long Haul optical and data networks. CoreOptics advocates for open optical communication systems that can efficiently transmit data across various rates and fiber types. Its innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is notable for enabling Tier 1 systems vendors and carriers to enhance network performance without overhauling existing fiber infrastructure. By eliminating the need for Optical Compensators and Second Stage Amplifiers, CoreOptics' products can significantly lower first-in deployment costs for customers, achieving reductions of up to 30%.

ClearCube Technology specializes in centralized and virtualized computing solutions, having pioneered the industry with the invention of the blade PC. The company provides a comprehensive range of specialized PCoIP desktop zero clients, which connect to optimized compute and storage host platforms tailored for different user needs, including both task-oriented and highly specialized engineering applications. ClearCube's product offerings include secure zero clients with integrated security features, designed for seamless compatibility with VMware Horizon virtualization products. Their solutions are widely adopted across various sectors, including federal agencies, healthcare, and finance, where they are valued for their ability to enhance security and reduce costs in centralization and virtualization efforts. ClearCube's commitment to meeting diverse IT requirements is further exemplified through their provision of ready-to-ship VDI endpoints and customizable hardware, ensuring optimal performance and expert support for businesses across multiple industries.

Axxom is a software development business that specializes in distribution, logistics, and production automation business solutions.

Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.

Vividence offers e-businesses with market information services and evaluation applications. It provides consulting services that focus on online customer experience, market trends, and industry strategies. Vividence enables individuals to earn gift cards by evaluating and giving feedback on e-commerce sites. Vividence was founded in 1998 and is based in San Mateo, California.

NanoGram Corporation is a nanotechnology company focused on developing and manufacturing advanced products for photovoltaics, electronics, and displays. It offers a customized application-specific nanotechnology platform that produces nanoscale compositions for various sectors, including optical, electronic, imaging, biomedical, and energy applications. The company has successfully incubated and spun out two firms, NeoPhotonics and NanoGram Devices. With a presence in Japan through its Tokyo office and a strategic partnership with Nagase & Co., Ltd / Nagase ChemteX Corporation, NanoGram is expanding its footprint in the region. Additionally, its office in Seoul, South Korea, supports its growth in the Korean market.

Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.

Impress Software Solutions, Inc. specializes in developing packaged integration applications that facilitate the integration of project management and geographical information systems with SAP. Its key products include Impress for EPM, which synchronizes project-related data between SAP PM/PS and platforms like Microsoft Project or Primavera, and Impress for GIS, which connects SAP assets with GIS features to maintain accurate asset information across systems. The company offers solutions for plant turnarounds, routine maintenance, information technology, capital projects, and spatial asset management. Its clientele spans various industries, including energy and utilities, oil and gas, aerospace and defense, chemicals, and engineering and construction. Founded in 1997 and headquartered in Waltham, Massachusetts, with additional offices in Hannover, Germany, and Huizerstraatweg, the Netherlands, Impress Software Solutions operates as a subsidiary of Impress Software GmbH and has established partnerships with notable organizations such as Accenture, ESRI, Microsoft, and Primavera.

Streaming21 is a solution provider of seamless on-demand and IP broadcasting service platform for connected digital home.

Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Cambridge Broadband Networks Limited specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers both in the United Kingdom and internationally. The company's flagship product, VectaStar, is a multipoint microwave platform that facilitates mobile backhaul, enterprise access, and small cell network solutions. This includes offerings such as VectaStar Gigabit for macro backhaul and enterprise access, and VectaStar Metro for multipoint microwave backhaul. Additionally, the company provides a comprehensive network management system and various support services, including consultancy, training, and project management, to assist operators in designing and deploying microwave backhaul networks. Founded in 1999 and headquartered in Cambridge, the company addresses the growing demand for enhanced network capacity and efficiency in the face of increasing mobile data usage.

TANTAU Software Inc. is a leading provider of software and services that enable enterprises to conduct high-volume, secure, mobile ecommerce transactions while maintaining direct access to their customer. TANTAU's blue-chip customer base includes major financial institutions and stock exchanges around the world. Strategic alliances include Nokia, Hewlett-Packard, Compaq, NEON Systems and Baltimore Technologies. TANTAU is a member of the WAP Forum and Radicchio, the global industry consortium that promotes security for wireless ecommerce. Headquartered in Austin, Texas, TANTAU is a global company with development and sales offices around the world, including Australia, Finland, Germany, Switzerland, the United Kingdom and the United States.

HepaVec AG is a privately held biotechnology company, focused on the development of novel therapeutic products for addressing malignant and genetic liver diseases, and on cell engineering of hepatocytes (liver cells). HepaVec has developed new gene transfer systems (vectors), derivatives of baculovirus and an ovine (sheep) adenovirus (OAV), which enable efficient and specific delivery of therapeutic genes into human liver cells. In the combat against liver cancer, HepaVec's lead product regulates the cell cycle to selectively drive cancer cells to programmed cell death (apoptosis) and is scheduled to enter a Phase I/II clinical trial in 2000.

PolyTrax Information Technology AG is a logistics and supply chain company located in Germany. The company specializes in developing power line communications technology that enables communication within buildings by utilizing existing power cables as the network infrastructure. This innovative approach aims to enhance connectivity and streamline communications in various environments, leveraging the existing electrical setup to provide efficient networking solutions.

Gold Wire Technology is a U.S.-based software company that specializes in network configuration management tools designed for large data communication distributors. Founded in 1997 and acquired by Intelliden in 2004, the company develops and supports solutions that ensure the integrity of multi-vendor infrastructures for enterprises operating in sectors such as financial services, retail, automotive, healthcare, and pharmaceuticals. Gold Wire Technology's software enables effective control and management of service configurations for internet service providers, focusing on the needs of organizations that rely on revenue or compliance-critical networks.

EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in the development of innovative pharmaceutical products aimed at treating pain and cancer. The company focuses on creating safe and effective prescription pain management solutions that utilize a topical delivery system, distinguishing itself from traditional systemic or transdermal methods. EpiCept is committed to exploring partnerships for co-marketing, co-promotion, licensing, and distribution with third-party collaborators to expand its reach in the market. The company's products are supported by a robust patent portfolio, reflecting its dedication to protecting its innovations and capitalizing on the significant market potential of its offerings.

Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers proteinarray services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development. In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions. Zeptosens was founded in 2002 and is headquartered in Wilderswil, Switzerland.

Neolinear is a software developer specializing in analog and mixed-signal silicon design. The company's technology plays a crucial role in the development of mixed-signal chips that integrate both analog and digital circuitry, primarily targeting the consumer and communications markets. As semiconductors become more differentiated by their analog components, Neolinear's rapid analog design solutions are essential for enhancing the performance and functionality of these chips.

A development stage biotechnology company with products for cardiovascular, cancer and inflammatory diseases.

Definiens is a company that specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. Its software offers detailed insights from whole tissue slides, cell-based assays, and full-body scans, enabling users to correlate this information with data from various sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating new knowledge, thereby enhancing decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, Definiens aims to advance research fields, contribute to the development of personalized medicine, and improve patient quality of life. The company also maintains offices across the United States.

Curacyte GmbH is a biopharmaceutical company based in Munich, Germany, founded in 2001. It specializes in developing innovative therapeutics for acute and critical care, focusing on areas such as hematology, antithrombosis, and oncology. The company's research efforts aim to create advanced biopharmaceutics that address urgent medical needs, providing new treatment options for patients with critical diseases.

WILEX a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II substance for the treatment of pancreatic and breast cancer. The company's products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.

Ark Therapeutics is a biotechnology company that develops products and therapies for vascular diseases and cancer.

Transave is a biotechnology research company that develops medicines and treatments for lung diseases.

TravelTainment develops software solutions for the travel distribution on the Internet and at travel agencies.

CyDex specializes in drug delivery solutions like licensing and commercializing cyclodextrins for pharmaceutical and biotechnology uses.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

TANTAU Software Inc. is a leading provider of software and services that enable enterprises to conduct high-volume, secure, mobile ecommerce transactions while maintaining direct access to their customer. TANTAU's blue-chip customer base includes major financial institutions and stock exchanges around the world. Strategic alliances include Nokia, Hewlett-Packard, Compaq, NEON Systems and Baltimore Technologies. TANTAU is a member of the WAP Forum and Radicchio, the global industry consortium that promotes security for wireless ecommerce. Headquartered in Austin, Texas, TANTAU is a global company with development and sales offices around the world, including Australia, Finland, Germany, Switzerland, the United Kingdom and the United States.

Infitel International is a provider of solutions for telecommunications value-added services based on intelligent networks (IN platforms).

Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.

Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.

Breonics focuses on biomedical research and development, specifically in the area of organ and tissue transplants. The company has developed Exsanguinous Metabolic Support (EMS) technology, which significantly expands the criteria for organ donation. This innovative technology addresses the limitations that currently restrict access to potential kidney donors, allowing healthcare practitioners to maintain the oxidative metabolism and function of organs while they are isolated from the human body. As a result, EMS has the potential to double the number of transplantable kidneys available worldwide, ultimately improving outcomes for patients in need of transplants.

Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases. It discovers and develops antigens and adjuvants, which are derived from its proprietary technology platforms. The company was founded in 1998 and is headquartered in Vienna, Austria.

Axxima Pharmaceuticals is a drug discovery and development company focused on creating innovative antibiotic and antiviral therapies. The company specializes in developing small molecule compounds that inhibit signal transduction pathways essential for the survival of various pathogens. By leading research in pathogen-host signal transduction, Axxima aims to address critical challenges in infectious disease treatment and contribute to the advancement of medical science.

Impress Software Solutions, Inc. specializes in developing packaged integration applications that facilitate the integration of project management and geographical information systems with SAP. Its key products include Impress for EPM, which synchronizes project-related data between SAP PM/PS and platforms like Microsoft Project or Primavera, and Impress for GIS, which connects SAP assets with GIS features to maintain accurate asset information across systems. The company offers solutions for plant turnarounds, routine maintenance, information technology, capital projects, and spatial asset management. Its clientele spans various industries, including energy and utilities, oil and gas, aerospace and defense, chemicals, and engineering and construction. Founded in 1997 and headquartered in Waltham, Massachusetts, with additional offices in Hannover, Germany, and Huizerstraatweg, the Netherlands, Impress Software Solutions operates as a subsidiary of Impress Software GmbH and has established partnerships with notable organizations such as Accenture, ESRI, Microsoft, and Primavera.

Morphochem is a biotechnology company focused on research and development in the pharmaceutical sector. The company is innovating an intravenous therapy for Clostridium difficile infection (CDI), utilizing a novel antibacterial compound known as MCB3681. By concentrating on the high-speed parallel synthesis of new chemical entities, Morphochem aims to discover and develop drug candidates that address unmet medical needs in various therapeutic areas. The company's efforts are directed towards making significant advancements in treatment options for patients suffering from CDI.

EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in the development of innovative pharmaceutical products aimed at treating pain and cancer. The company focuses on creating safe and effective prescription pain management solutions that utilize a topical delivery system, distinguishing itself from traditional systemic or transdermal methods. EpiCept is committed to exploring partnerships for co-marketing, co-promotion, licensing, and distribution with third-party collaborators to expand its reach in the market. The company's products are supported by a robust patent portfolio, reflecting its dedication to protecting its innovations and capitalizing on the significant market potential of its offerings.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

VPIsystems, formerly known as VPI Virtual Photonics, develops and markets network planning software and services for the telecommunications industry, both in the United States and internationally. The company offers products such as Photonic Design Automation, which models and optimizes photonic components, and OnePlan, an integrated system that assists communications service providers, systems integrators, and manufacturers in transitioning to IP-based networks. VPIsystems aims to enhance the efficiency of network planning and engineering processes through predictive network analytics, enabling clients to optimize network integration and improve overall network reliability. The company serves a diverse clientele, including wireline and wireless carriers, broadband providers, and equipment manufacturers. Founded in 1997, VPIsystems is headquartered in Holmdel, New Jersey, with additional offices in Europe, Asia, and Australia, and maintains strategic alliances with notable firms such as Accenture and HP.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

MediGene AG is a biotechnology company focused on immuno-oncology, specializing in the development of differentiated T Cell Receptor engineered T cell (TCR-T) therapies for treating various solid tumor indications with high unmet medical needs. Its primary operating segments are Immunotherapies and Other products, with Immunotherapies comprising T-cell receptor-based adoptive T-cell therapy and DC vaccines. MediGene operates globally, with significant revenue generated from its operations in Germany.